Literature DB >> 25815646

Usefulness of dual-phase 18F-FDG PET/CT for diagnosing small pancreatic tumors.

Natsuko Kawada1, Hiroyuki Uehara, Takuya Hosoki, Motohisa Takami, Hisakazu Shiroeda, Tomiyasu Arisawa, Yasuhiko Tomita.   

Abstract

OBJECTIVES: The usefulness of dual-phase F-fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT) for pancreatic tumors was investigated including numerous small tumors.
METHODS: Consecutive 116 patients with solid pancreatic tumors were subjected. Maximum standard uptake values (SUVmax) at 1 and 2 hours after FDG injection were defined as early and delayed SUVmax, respectively. Receiver operating characteristic curve was used to determine the optimal cutoff value of early SUVmax. Diagnostic accuracy of dual-phase FDG PET/CT was compared with that of single phase.
RESULTS: The mean ± SD tumor size was 25 ±12 mm in diameter. The level of early SUVmax and proportion of elevated SUVmax in delayed phase were significantly higher in malignancy than those in benignancy for less than 25 mm tumors (4.1 ± 2.6 vs 1.9 ± 0.5, P < 0.001; 89% vs 17%, P < 0.0001) although they did not reach statistical significance for greater than or equal to 25 mm tumors. When diagnostic criteria of dual-phase FDG PET/CT for less than 25 mm tumors were determined as (1) early SUVmax greater than or equal to 2.1 and/or (2) delayed SUVmax greater than early SUVmax, sensitivity, specificity, and over all accuracy of dual-phase FDG PET/CT were better than that of single phase for less than 25 mm tumor (93%, 83%, and 91% vs 79%, 83%, and 80%, respectively).
CONCLUSIONS: Dual-phase FDG PET/CT might be useful for diagnosing small pancreatic tumors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25815646     DOI: 10.1097/MPA.0000000000000313

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  8 in total

1.  Preoperative 2-[18F]FDG PET-CT aids in the prognostic stratification for patients with primary ampullary carcinoma.

Authors:  Pei-Ju Chuang; Hsiu-Po Wang; Yu-Jen Lin; Chieh-Chang Chen; Yu-Wen Tien; Min-Shu Hsieh; Shih-Hung Yang; Ruoh-Fang Yen; Chi-Lun Ko; Yen-Wen Wu; Mei-Fang Cheng
Journal:  Eur Radiol       Date:  2021-04-17       Impact factor: 5.315

Review 2.  Imaging modalities for characterising focal pancreatic lesions.

Authors:  Lawrence Mj Best; Vishal Rawji; Stephen P Pereira; Brian R Davidson; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2017-04-17

3.  The exploration of quantitative intra-tumoral metabolic heterogeneity in dual-time 18F-FDG PET/CT of pancreatic cancer.

Authors:  Guorong Jia; Jian Zhang; Rou Li; Jianhua Yan; Changjing Zuo
Journal:  Abdom Radiol (NY)       Date:  2021-04-18

4.  Early SUVmax is the best predictor of axillary lymph node metastasis in stage III breast cancers.

Authors:  Jiangong Zhang; Xun Shi; Yong Xiao; Chao Ma; Gang Cao; Yongbo Liu; Yonggang Li
Journal:  Quant Imaging Med Surg       Date:  2021-05

5.  High Uptake of FDG Along a Biliary Stent.

Authors:  Yasunari Nagasaki; Hiromichi Yamane; Nobuaki Ochi; Yoshihiro Honda; Nagio Takigawa
Journal:  Clin Nucl Med       Date:  2016-11       Impact factor: 7.794

6.  Clinically determined type of 18F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer.

Authors:  Jae Uk Chong; Ho Kyoung Hwang; Jin Ho Lee; Mijin Yun; Chang Moo Kang; Woo Jung Lee
Journal:  PLoS One       Date:  2017-02-24       Impact factor: 3.240

7.  Investigation of Association Between Borderline Pancreatic Head Cancer and Glucose Uptake by Using Positron-Emission Tomographic Studies.

Authors:  Ying Zhang; Lei Qin; Changming Zhang
Journal:  Med Sci Monit       Date:  2017-10-16

8.  A small pancreatic hamartoma with an obstruction of the main pancreatic duct and avid FDG uptake mimicking a malignant pancreatic tumor: a systematic case review.

Authors:  Hiroaki Nagano; Masayuki Nakajo; Yoshihiko Fukukura; Yoriko Kajiya; Atsushi Tani; Sadao Tanaka; Mari Toyota; Toru Niihara; Masaki Kitazono; Toyokuni Suenaga; Takashi Yoshiura
Journal:  BMC Gastroenterol       Date:  2017-12-06       Impact factor: 3.067

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.